These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6262159)

  • 21. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
    Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
    J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biological activity of residual cell-substrate DNA.
    Peden K; Sheng L; Pal A; Lewis A
    Dev Biol (Basel); 2006; 123():45-53; discussion 55-73. PubMed ID: 16566436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Examination of poliovaccines for the presence of SV40 sequences.
    Sangar DV; Wood DJ; Minor PD
    Dev Biol Stand; 1998; 94():221-5. PubMed ID: 9776243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Restricted infectivity of ecotropic type C retroviruses in mouse teratocarcinoma cells: studies on viral DNA intermediates.
    Yang WK; d'Auriol L; Yang DM; Kiggnas JO; Ou C; Périès J; Emanoil-Ravicovitch R
    J Supramol Struct; 1980; 14(2):223-32. PubMed ID: 6262577
    [TBL] [Abstract][Full Text] [Related]  

  • 25. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrovirus screening of vaccine cell substrates.
    Khan AS
    Dev Biol Stand; 1996; 88():157-62. PubMed ID: 9119131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Killed polio virus vaccine in the control of poliomyelitis in Finland.
    Lapinleimu K
    Ann Clin Res; 1982 Dec; 14(5-6):199-203. PubMed ID: 6303196
    [No Abstract]   [Full Text] [Related]  

  • 28. [End phase challenges of poliomyelitis eradication programme realization].
    Jarzabek Z
    Przegl Epidemiol; 2005; 59(1):59-68. PubMed ID: 16013411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paralytic poliomyelitis--United States, 1980-1994.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 1997 Jan; 46(4):79-83. PubMed ID: 9048844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains.
    Laassri M; Lottenbach K; Belshe R; Wolff M; Rennels M; Plotkin S; Chumakov K
    J Infect Dis; 2005 Dec; 192(12):2092-8. PubMed ID: 16288372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumorigenicity assessments of Per.C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line.
    Ledwith BJ; Lanning CL; Gumprecht LA; Anderson CA; Coleman JB; Gatto NT; Balasubramanian G; Farris GM; Kemp RK; Harper LB; Barnum AB; Pacchione SJ; Mauer KL; Troilo PF; Brown ER; Wolf JJ; Lebronl JA; Lewis JA; Nichols WW
    Dev Biol (Basel); 2006; 123():251-63; discussion 265-6. PubMed ID: 16566451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Worldwide eradication of poliomyelitis].
    Rasch G; Schreier E; Kiehl W; Kurth R
    Wien Klin Wochenschr; 2001 Oct; 113(20-21):839-45. PubMed ID: 11732120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus type 18 DNA in so-called HEP-2, KB and FL cells--further evidence that these cells are HeLa cell derivatives.
    Ogura H; Yoshinouchi M; Kudo T; Imura M; Fujiwara T; Yabe Y
    Cell Mol Biol (Noisy-le-grand); 1993 Jul; 39(5):463-7. PubMed ID: 8397027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mouse chorionic gonadotropin beta-subunit-like (muCG beta l) molecule produced by tumor cells elicits the switch of T-cell immunity response from TH2 to TH1 in mice immunized with DNA vaccine based on rhesus monkey homologous CG beta (rmCG beta).
    Shi SQ; Peng JP; Xu L; Yang Y; Chen Y
    J Gene Med; 2005 Jan; 7(1):87-96. PubMed ID: 15517553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine.
    Wood DJ; Heath AB; Kersten GF; Hazendonk T; Lantinga M; Beuvery EC
    Biologicals; 1997 Mar; 25(1):59-64. PubMed ID: 9167009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of simian virus 40 large T antigen in 18 autopsied malignant mesothelioma patients in Japan.
    Jin M; Sawa H; Suzuki T; Shimizu K; Makino Y; Tanaka S; Nojima T; Fujioka Y; Asamoto M; Suko N; Fujita M; Nagashima K
    J Med Virol; 2004 Dec; 74(4):668-76. PubMed ID: 15484269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk management in a polio-free world.
    Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
    Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poliovirus vaccine options.
    Zimmerman RK; Spann SJ
    Am Fam Physician; 1999 Jan; 59(1):113-8, 125-6. PubMed ID: 9917578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.